Everolimus, a kinase inhibitor already approved for treating kidney cancer, has been approved as a treatment for slowly growing, benign tumors in patients with tuberous sclerosis, the Food and Drug Administration announced on Nov. 1.Everolimus, marketed as Afinitor for kidney cancer, was approved for treating subependymal giant cell astrocytoma (SEGA) associated with the rare genetic disorder, in cases in which these tumors cannot be treated surgically. (Everolimus is also approved for prophylaxis...